BlackSky Wins Multimillion-Dollar Contract with New International Defense Customer for Gen-3 and Gen-2 Assured Services
'This contract illustrates how BlackSky's reliable real time, commercial space-based intelligence services can be used as an important tool for modern defense and intelligence organizations engaged across the full spectrum of grey-zone conflicts."
'This contract illustrates how BlackSky's reliable fully integrated real-time, commercial space-based intelligence services can be used as an important tool for modern defense and intelligence organizations engaged across the full spectrum of grey-zone conflicts worldwide,' said Brian O'Toole, BlackSky CEO. 'BlackSky's end-to-end automated architecture uniquely gives our most demanding customers the ability to task and receive high-cadence imagery and AI-enabled analytics starting on day one.'
As part of the agreement, the customer will receive immediate, subscription-based access to Assured services, which guarantees tasking capacity for persistent monitoring over a customer's areas of interest. BlackSky will also upgrade the customer's existing ground station and mission operations center with direct-downlink and uplink communications capabilities for faster, locally controlled intelligence.
'Our international allied customers continue to lead as early adopters, constantly developing novel applications for AI-enabled change-based monitoring,' said O'Toole. 'For this contract, BlackSky will also be optimizing the ground segment, making the customer's overall sovereign architecture forward-compatible with the high processing volumes associated with low-latency, high-cadence space-based monitoring.'
The customer will use BlackSky's automated Spectra ® AI-enabled tasking and analytics platform to order and fuse data from Gen-3 and Gen-2 satellites, enabling the detection, identification and classification of objects of interest, such as vehicles, aircraft and vessels, with no humans in the loop. Gen-3 capabilities build upon the proven architecture of Gen-2, allowing for continued innovation and rapid deployment of new technologies.
BlackSky has proprietary in-house satellite design and agile manufacturing, constellation operations and end-to-end advanced software development capabilities. This vertically integrated approach gives the company the ability to quickly develop, produce and deploy reliable space-based intelligence solutions at disruptive speed, scale and economics.
About BlackSky
BlackSky is a real-time, space-based intelligence company that delivers on-demand, high frequency imagery, analytics, and high-frequency monitoring of the most critical and strategic locations, economic assets, and events in the world. BlackSky owns and operates one of the industry's most advanced, purpose-built commercial, real-time intelligence systems that combines the power of the BlackSky Spectra® tasking and analytics software platform and our proprietary low earth orbit satellite constellation.
With BlackSky, customers can see, understand and anticipate changes for a decisive strategic advantage at the tactical edge, and act not just fast, but first. BlackSky is trusted by some of the most demanding U.S. and international government agencies, commercial businesses, and organizations around the world. BlackSky is headquartered in Herndon, VA, and is publicly traded on the New York Stock Exchange as BKSY. To learn more, visit www.blacksky.com and follow us on X.
Forward-Looking Statements
Certain statements in this press release may contain forward-looking statements within the meaning of the federal securities laws with respect to BlackSky, including statements related to expected payments under BlackSky's contracts with customers and BlackSky's ability to develop, produce and deploy reliable space-based intelligence solutions. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, forward-looking statements reflect our expectations, plans, or forecasts of future events and views as of the date of this communication. We anticipate that subsequent events and developments will cause their assessments to change. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties are identified and discussed in BlackSky's disclosure materials filed from time to time with the SEC which are available at the SEC's website at http://www.sec.gov or on BlackSky's Investor Relations website at https://ir.blacksky.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
The three-year shareholder returns and company earnings persist lower as Bath & Body Works (NYSE:BBWI) stock falls a further 6.5% in past week
Many investors define successful investing as beating the market average over the long term. But if you try your hand at stock picking, you risk returning less than the market. Unfortunately, that's been the case for longer term Bath & Body Works, Inc. (NYSE:BBWI) shareholders, since the share price is down 20% in the last three years, falling well short of the market return of around 57%. Even worse, it's down 13% in about a month, which isn't fun at all. After losing 6.5% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the three years that the share price fell, Bath & Body Works' earnings per share (EPS) dropped by 4.3% each year. This reduction in EPS is slower than the 7% annual reduction in the share price. So it seems the market was too confident about the business, in the past. The less favorable sentiment is reflected in its current P/E ratio of 7.50. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. It might be well worthwhile taking a look at our free report on Bath & Body Works' earnings, revenue and cash flow. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Bath & Body Works, it has a TSR of -14% for the last 3 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! A Different Perspective While the broader market gained around 23% in the last year, Bath & Body Works shareholders lost 6.3% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 8%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Bath & Body Works better, we need to consider many other factors. Take risks, for example - Bath & Body Works has 3 warning signs (and 1 which can't be ignored) we think you should know about. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Wire
18 minutes ago
- Business Wire
BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its TAH System has been accepted into the U.S. Food and Drug Administration's (FDA) prestigious Total Product Life Cycle (TPLC) Advisory Program, also known as the TAP program. This milestone further solidifies BiVACOR's collaboration with the FDA following the TAH's earlier recognition this year as a Breakthrough Device. This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology. The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with urgency and magnitude of our mission. Share The TAP program is a transformative FDA initiative designed to accelerate the development and patient access to high-impact medical technologies. Entry into the program provides BiVACOR with proactive, strategic engagement with the FDA throughout the entire product life cycle, from development to commercialization, supporting more efficient, risk-informed decision-making. TAP participation is reserved for breakthrough-designated devices with the potential to significantly improve patient outcomes for serious or life-threatening conditions. 'Acceptance into the TAP program marks a major milestone not just for BiVACOR, but for the field of mechanical circulatory support as a whole,' said Daniel Timms, Founder and Chief Technology Officer of BiVACOR. 'The BiVACOR TAH has the potential to fundamentally redefine the standard of care for patients with end-stage heart failure. TAP access gives us a powerful framework for working hand-in-hand with the FDA to bring this technology to the patients who need it most.' The BiVACOR TAH is intended for use as a bridge to transplant in adults with severe, irreversible biventricular or univentricular heart failure, particularly for patients who cannot be treated with traditional left ventricular assist devices (LVADs). The system employs a magnetically levitated centrifugal pump, inspired by space and industrial technologies, which provides continuous, pulsatile, and physiologically responsive cardiac support. The FDA's acceptance letter to BiVACOR emphasized that the TAP program's inclusion reflects the agency's confidence in the technology's potential to transform clinical practice. As part of the program, BiVACOR will receive more regulatory guidance, earlier identification of scientific and evidentiary gaps, and greater coordination among stakeholders, including payers and patient advocacy groups. 'This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology,' said William Cohn, MD, BiVACOR Chief Medical Officer and renowned cardiac surgeon. 'The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with the urgency and magnitude of our mission to bring a durable, fully implantable artificial heart to patients with no other options.' The TAP program was established as part of the FDA's efforts to modernize device development oversight and ensure the U.S. remains at the forefront of medical innovation. The program currently operates as a pilot under the Center for Devices and Radiological Health (CDRH), with acceptance based on strict criteria outlined in the Federal Register (87 FR 61605). BiVACOR's participation in TAP follows several recent milestones for the company, including its first-in-human implant as a bridge to support a patient awaiting a cardiac transplant. The company is now progressing toward expanded clinical trials in the U.S. and internationally. For more information on the FDA's TAP program, visit: Participation in the FDA's Total Product Life Cycle Advisory Program (TAP) does not imply FDA approval, clearance, or authorization. Inclusion in the TAP Pilot does not guarantee future marketing authorization or a regulatory outcome. The BiVACOR TAH is currently used as an investigational device and is not approved for commercial use. About BiVACOR BiVACOR ® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at
Business Upturn
38 minutes ago
- Business Upturn
Built with Now: Staffbase announces integration with ServiceNow to deliver seamless digital employee experience
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — Staffbase today announced a product integration with ServiceNow to unify digital workflows with internal communications, helping organizations extend the power of the ServiceNow AI Platform across the entire workforce. The joint effort enables Staffbase to create better experiences and drive value for customers by surfacing critical ServiceNow workflows in a way that is intuitive, accessible, and engaging for all employees, including frontline and non-desk workers. As a Build Partner, the certified Staffbase–ServiceNow integration provides embedded ServiceNow widgets and search functionality within the Staffbase platform and is available via the Staffbase website and the ServiceNow Store. Staffbase ensures that ServiceNow workflows are easily discoverable and usable for all employees through its mobile-first communications platform, solving a potential disconnect between digital systems and employee adoption. The result: higher ServiceNow adoption, faster task resolution, and greater ROI on digital investments. 'This integration reinforces our commitment to helping enterprises create a unified digital employee experience,' said David Maffei, Staffbase GM and SVP of the Americas. 'ServiceNow is the engine behind many critical workflows. Staffbase ensures those workflows reach every employee in a way that's intuitive, accessible, and actionable, especially for those outside of a traditional office setting.' 'Partnerships succeed best when we collaborate with a clear focus to drive successful customer outcomes,' said Michael Park, Senior Vice President, Global Partnerships and Channels at ServiceNow. 'Staffbase's integration with ServiceNow will empower customers to streamline workflows, enhance efficiency, and unlock new value on the ServiceNow AI Platform. I am thrilled to see the continued innovation we will achieve together to help organizations excel in today's dynamic business environment.' About Staffbase Staffbase is the leading employee communications cloud, equipping many of the world's leading companies with solutions to inspire every employee with motivating communication. With over 2000 customers, Staffbase helps organizations such as Adidas, Alaska Airlines, Audi, Blue Apron, DHL, and Whataburger to inspire their people to achieve great things together. Staffbase connects companies with their employees through a branded employee app, intranet, email, SMS, digital signage, and Microsoft 365 integrations, all of which can be managed through a single platform. Staffbase was named a leader in the 2024 Gartner® Magic Quadrant™ for Intranet Packaged Solutions. Staffbase is headquartered in Chemnitz, Germany and New York City. Please visit for more information. ServiceNow, the ServiceNow logo, Now, Now Platform, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Media contactMelanie BochmannSenior Director of Communications [email protected]
